According to filings with the U.S. Securities and Exchange Commission, Akadeum Life Sciences is raising up to $3,427,230.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Akadeum Life Sciences
Akadeum Life Sciences is a biotechnology company that develops and commercializes next-generation microbubble-based cell separation technologies to advance human health. Using its proprietary buoyant microbubble platform, Akadeum provides innovative solutions for sample preparation and target isolation, enabling quick, gentle enrichment of analytes such as cells while maintaining their health and physiology. The company offers cell separation products and kits for cell therapy manufacturing, purification, culture cleanup, and small-scale immunology research, including GMP-grade and clinical-ready tools that support the translation of cell therapeutics from research through commercialization. Akadeums technology is designed to solve long-standing challenges across research, diagnostic, and therapeutic markets by improving cell quality, potency, persistence, and efficiency, and can deliver up to a 40% reduction in overall cell therapy manufacturing costs. Through these advances in separation science, Akadeum positions itself as a leader in floatation-based target isolation, empowering researchers and clinicians to drive breakthroughs in diagnostics, therapeutics, and basic research.

To learn more, visit https://www.akadeum.com/
LinkedIn: https://www.linkedin.com/company/akadeum-life-sciences-inc-

Contact:
James Militello, Chief Financial Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.